{"id":391113,"date":"2016-06-22T00:00:00","date_gmt":"2016-06-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0002-2016-biopharma-malignant-melanoma-current-treatment-physician-insights-eu5-2016\/"},"modified":"2026-03-31T09:02:03","modified_gmt":"2026-03-31T09:02:03","slug":"cutron0002-2016-biopharma-malignant-melanoma-current-treatment-physician-insights-eu5-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0002-2016-biopharma-malignant-melanoma-current-treatment-physician-insights-eu5-2016\/","title":{"rendered":"Malignant Melanoma | Current Treatment: Physician Insights | EU5 | 2016"},"content":{"rendered":"<p>Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced by disease stage, resectability, and in the unresectable or metastatic setting, <i>BRAF-<\/i>mutation status. The malignant melanoma landscape has transformed since 2011: CTLA-4 inhibitors, PD-1 inhibitors, and BRAF\/MEK inhibitors are now key treatment options for unresectable disease while adjuvant cytokine therapy remains the mainstay for early-stage disease. This analysis provides insight on current use of approved therapies for malignant melanoma in the EU5 and on factors driving physicians\u2019 prescribing decisions.<\/p>\n","protected":false},"template":"","class_list":["post-391113","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-product-current-treatment","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391113\/revisions"}],"predecessor-version":[{"id":394236,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391113\/revisions\/394236"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}